© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
December 06, 2022
Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
December 05, 2022
According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
December 04, 2022
SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.
December 03, 2022
Weigh in on this month's survey question. The poll will be open until December 16, 2022.
December 03, 2022
In an effort to educate the public on GA, Prevent Blindness has created a variety of resources for patients in English and Spanish.
December 01, 2022
Despite the latest advances in anti-VEGF therapy, a small group of patients do not achieve improved vision. Ophthalmologists are looking for options.
November 18, 2022
LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.
November 18, 2022
Diabetes can damage the eyes over time and cause vision loss, even blindness. Delaying the disease can also delay any onset of vision problems, including diabetic retinopathy and diabetic macular edema.
November 17, 2022
Mount Sinai study is the first to identify that heart attack, stroke and heart failure are linked to a specific type of age-related macular degeneration.
November 17, 2022
Ophthalmologists have learned to optimize their use of traditional anti-VEGF therapies and are now incorporating newer therapies like brolucizumab for managing retinal diseases, and in the not-so-distant future they can look forward to gaining familiarity with faricimab and using a new delivery system for ranibizumab.